DMW – Klinischer Fortschritt, Inhaltsverzeichnis Dtsch Med Wochenschr 2011; 136(48): 2492-2495DOI: 10.1055/s-0031-1297275 Verdauungs- und Stoffwechselkrankheiten | Commentary Gastroenterologie, Onkologie © Georg Thieme Verlag KG Stuttgart · New York Magenkarzinom – Was gibt’s Neues? Gastric cancer – what’s new?M. Möhler1 , J. T. Siveke2 , R. M. Schmid2 1I. Medizinische Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz 2II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München Artikel empfehlen Abstract Artikel einzeln kaufen Schlüsselwörter Magenkarzinom - S3-Leitlinie Keywords gastric cancer - guideline Volltext Referenzen Literatur 1 Bang Y, Van Cutsem E, Feyereislova A. et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376 687-697 2 Cunningham D, Allum W, Stenning S. et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 335 11-20 3 Gebski V, Burmeister B, Smithers B. et al . Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet. 2007; 8 226-234 4 Gotoda T, Yanagisawa A, Sasako M. et al . Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000; 3 219-225 5 Heiss M, Murawa P, Koralewski P. et al . The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010; 127 2209-2221 6 Kinkel K, Lu Y, Both M, Warren R, Thoeni R. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002; 224 748-756 7 Kwee R, Kwee T. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007; 25 2107-2116 8 Lutz M, Wilke H, Wagener D. et al . Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2007; 25 2580-2585 9 Moehler M, Al-Batran S -E, Andus T. et al . S3-Leitlinie „Magenkarzinom“ – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032 – 009-OL). Z Gastroenterol. 2011; 49 461-531 10 Moehler M, Mueller A, Trarbach T. et al . Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol. 2011; 22 1358-1366 11 Okines A, Norman A, McCloud P, Kang Y, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009; 20 1529-1534 12 Paoletti X, Oba K, Burzykowski T. et al . Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010; 303 1729-1737 13 Puli S, Batapati Krishna Reddy J, Bechtold M, Antillon M, Ibdah J. How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review. World J Gastroenterol. 2008; 14 4011-4019 14 SIGN .Management of oesophageal and gastric cancer. NHS. 2006 15 Ychou M, Boige V, Pignon J. et al . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29 1715-1721 PD Dr. med. Markus Möhler I. Medizinische Klinik und PoliklinikUniversitätsmedizin der Johannes Gutenberg-Universität Langenbeckstr. 1 55101 Mainz Telefon: 06131/176076 Fax: 06131/176472 eMail: markus.moehler@unimedizin-mainz.de